General Information
Lilly Obesity-DM2 GZGQ
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of OnceDaily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
| Protocol | J2A-MC-GZGQ |
|---|---|
| Identifier | PO 4900797823 |
| UID | 4f0789fe-2470-40f3-aae5-c0e6f20984b2 |
| Status | Pending Closeout |
| Phase | 3 |
| Category | Diabetes Type2/Obesity / Adult |
| Launch Year | 2023 |
| NCT Number | - |
| Created | 2023-02-13 15:22 |
| Last Updated | 2025-08-22 22:17 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2024-02-07 | No |
| Enrollment Open | 2023-07-11 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2023-06-26 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2025-09-18 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Loera, Yazmin | YLoera | No |
| Regulatory | Romero, Araselly | ARomero | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Eli Lilly and Company |
|---|---|
| Division | Lilly |
| Team | Lilly |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | LightSkyBlue |
| Currency | - |
